## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims:

- (Previously presented) Peripheral blood mononuclear cells (PBMC) comprising one or more suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
  - a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor;
  - b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC; and
  - c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce one or more recipient suppressor T cells.
- (Previously presented) A population of peripheral blood mononuclear cells (PBMC) comprising suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
  - a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor;
  - b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC:
  - c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce a PBMC population comprising one or more recipient suppressor T cells: and
  - d) wherein a recipient suppressor T cell population is produced by expanding said recipient suppressor T cells.
- (Previously presented) The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein said regulatory composition further comprises cytokines selected from the group consisting of IL-2 and IL-15.
- (Previously presented) The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein said recipient PBMC are enriched for CD4+ T cells.
- (Previously presented) The PBMC comprising suppressor T cells according to Claim 4, wherein said CD4+ cells are enriched for naïve CD4+ T cells.
- (Previously presented) The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein said recipient PBMC are enriched for CD8+ T cells.